https://www.diabesityrounds.com/a/oral-glp-1-drugs-a-committee-opinion-registry-numbers-and-an-early-phase-ii-signDiabesity Roundsen2026-10-18T05:26:54.051ZOral GLP-1 drugs: a committee opinion, registry numbers and an early Phase II signalhttps://www.diabesityrounds.com/a/oral-glp-1-agonist-hrs-7535-lowered-hba1c-in-phase-ii-trial-in-type-2-diabetesDiabesity Roundsen2026-10-18T05:01:02.722ZOral GLP-1 agonist HRS-7535 lowered HbA1c in Phase II trial in type 2 diabeteshttps://www.diabesityrounds.com/a/cgm-lowers-hba1c-in-adults-with-type-2-diabetes-not-using-insulin-in-primary-carDiabesity Roundsen2026-10-18T04:45:42.884ZCGM lowers HbA1c in adults with type 2 diabetes not using insulin in primary carehttps://www.diabesityrounds.com/a/ema-committee-backs-orforglipron-foundayo-for-weight-management-and-type-2-diabeDiabesity Roundsen2026-10-18T04:30:41.901ZEMA committee backs orforglipron (Foundayo) for weight management and type 2 diabeteshttps://www.diabesityrounds.com/a/oral-orforglipron-vs-dapagliflozin-on-metformin-achieve-2-hba1c-results-postedDiabesity Roundsen2026-10-18T04:15:55.698ZOral orforglipron vs dapagliflozin on metformin: ACHIEVE-2 HbA1c results posted